Sickle Cell Disease clinical trials
148 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
- A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
- Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
- RH Genotype Matched RBC Transfusions
- A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
- Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
- Oral Ketamine for Treatment of Vaso-Occlusive Pain
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- A Phase 2/3 Study in Adult and Adolescent Participants With SCD
- Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
- Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease
- The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
- Gene Editing For Sickle Cell Disease
- Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
- Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
- Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
- Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease
- Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
- A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease
- Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
- SickleFit Randomized Control Trial
- Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
- Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
- 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
- Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
- Sickle Cell Improvement: Enhancing Care in the Emergency Department
- Early Screening and Treatment of Heart Complication in Sickle Cell Disease
- Tocilizumab for Acute Chest Syndrome
- Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
- A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Sickle Cell Disease” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.